OAKLAND, Calif.--(BUSINESS WIRE)--Versanis Bio today announced the closing of its Series A financing of $70 million to advance the clinical development of bimagrumab, an activin receptor type II ...
A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also ...
BATON ROUGE, La. – A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater ...
A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also ...
Shares of Eli Lilly & Co. (NYSE: LLY) closed 2.80% higher for the week ended July 21, a week after Lilly said it would buy Versanis, a privately held clinical-stage biopharmaceutical company focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results